Quantcast
Last updated on April 16, 2014 at 10:23 EDT

Latest Eisai Stories

2013-11-25 08:28:22

TOKYO, Nov. 25, 2013 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, "Eisai") announced today that it has become a signatory to the Tuberculosis Drug Accelerator (TBDA) partnership, a groundbreaking initiative that aims to speed up the discovery of essential new treatments for tuberculosis (TB). (Logo: http://photos.prnewswire.com/prnh/20120413/MM87168LOGO ) Jointly launched in June 2012 through a collaborative agreement among seven...

2013-11-22 16:26:04

DUBLIN, November 22, 2013 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/7kx2mv/cns_therapeutics) have announced the addition of the "CNS Therapeutics - Global Strategic Business Report" [http://www.researchandmarkets.com/research/7kx2mv/cns_therapeutics ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) This report analyzes the worldwide markets for CNS Therapeutics...

2013-11-20 08:28:15

NEW YORK, Nov. 20, 2013 /PRNewswire/ -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (OTCQB: AVXL) announced today the appointment of Dr. Ottavio Arancio, MD, PhD to the Company's Scientific Advisory Board. Dr. Arancio is a cellular neurobiologist who has pioneered the field of mechanisms of synaptic dysfunction in Alzheimer's disease. He is Associate Professor of Pathology and Cell Biology at the Columbia University Medical Center and The Taub Institute for Research on...

2013-11-18 08:30:17

Representatives Will Use Educational Tool for Up to 65,000 Physicians WOODCLIFF LAKE, N.J. and BENSALEM, Pa., Nov. 18, 2013 /PRNewswire/ -- Eisai and BusinessOne Technologies announced today that Eisai Inc. is using the Maestro Market Access Mobile(TM) application to educate physicians about detailed coverage levels for Eisai's recently approved BELVIQ(®) (lorcaserin HCI) CIV. Market Access Mobile enables fact-based decisions and targeted strategies to increase clinical adoption and expand...

2013-11-18 08:28:37

WOODCLIFF LAKE, N.J. and SAN DIEGO, Nov. 18, 2013 /PRNewswire/ -- Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that a new data analysis from the BELVIQ(®) (lorcaserin HCl) Phase 3 clinical trial program will be presented at the American Heart Association 2013 Scientific Sessions, November 16-20 in Dallas, Texas. The following abstract highlighting BELVIQ data will be presented: -- The Effects of Lorcaserin on High-Sensitivity C-reactive Protein in...

2013-11-18 08:28:15

Study Presented at CNS Summit 2013 Suggests ANAVEX 2-73 Will Have Clinically Detectable and Meaningful Effect in Alzheimer's Disease, Especially When Combined With Aricept® NEW YORK, Nov. 18, 2013 /PRNewswire/ -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (OTCQB: AVXL) presented new data from a study evaluating ANAVEX 2-73 in a computer simulation model of Alzheimer's disease (AD) limited to symptomatic effects, which was presented during a poster session at the CNS...

2013-11-17 20:21:21

HATFIELD, England, November 18, 2013 /PRNewswire/ -- Eisai announces today that Halaven(R) (eribulin) will be marketed in selected countries within the Middle East region through a new partnership between Eisai EMEA (Europe, the Middle East, Africa, Russia and Oceania) and NewBridge Pharmaceuticals. Eribulin is indicated for the treatment of locally advanced or metastatic breast cancer, which has progressed after at least two chemotherapeutic regimens for advanced disease....

2013-11-11 08:27:48

PITTSBURGH, Nov. 11, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its U.S.-based subsidiary Mylan Pharmaceuticals Inc. has launched Rabeprazole Sodium Delayed-release Tablets, 20 mg. Rabeprazole Sodium Delayed-release Tablets are the generic version of Eisai Corporation's Aciphex(®) Tablets, and are indicated for short-term treatment in the healing and symptomatic relief of erosive or ulcerative gastroesophageal reflux disease, and for short-term treatment in...

2013-11-11 08:27:44

MUMBAI and BALTIMORE, November 11, 2013 /PRNewswire/ -- Pharma Major Lupin Limited (Lupin) announced today that its US subsidiary, Lupin Pharmaceuticals, Inc. (LPI) has launched its generic Rabeprazole Sodium delayed-release tablets, 20mg. Lupin had earlier received final approval from the US FDA for the same. Lupin's Rabeprazole Sodium delayed-release tablets, 20mg, are the generic equivalent of Eisai Inc.'s Aciphex(R) delayed-release tablets, 20mg, and are indicated...

2013-11-08 08:28:25

WOODCLIFF LAKE, N.J., Nov. 8, 2013 /PRNewswire/ -- Eisai Inc. announced today that ACIPHEX(®) Sprinkle(TM) Delayed-Release Capsules 5mg and 10mg will be available to eligible patients by prescription in the United States by November 8, 2013. (Logo: http://photos.prnewswire.com/prnh/20120413/MM87168LOGO ) ACIPHEX Sprinkle Delayed-Release Capsules 5mg and 10mg was approved by the U.S. Food and Drug Administration on March 26, 2013 for the treatment of Gastroesophageal Reflux Disease (GERD) in...